| abstract |
The present invention relates to the diagnosis and treatment of cancerous diseases, and more particularly to mediating cytotoxicity against tumor cells, most particularly as a means for initiating a cytotoxic response, optionally with one or more chemistries. It relates to the use of cancerous disease modifying antibodies (CDIVIB) in combination with therapeutic agents. The invention further relates to binding assays that utilize the CDMAB of the invention. [Selection] Figure 4 |